We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

34 hedge funds and large institutions have $50.9M invested in RVL Pharmaceuticals plc Ordinary Shares in 2018 Q4 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
34
Holders Change
+34
Holders Change %
–
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
34
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$12M
2
DM
Deerfield Management
New York
+$9.11M
3
SFM
Sphera Funds Management
Israel
+$7.38M
4
BC
Broadfin Capital
New York
+$4.23M
5
BlackRock
BlackRock
New York
+$3.8M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
GPP
1
Great Point Partners
Connecticut
$11.6M +$12M +1,500,000 New
DM
2
Deerfield Management
New York
$8.82M +$9.11M +1,138,256 New
SFM
3
Sphera Funds Management
Israel
$7.15M +$7.38M +922,200 New
BC
4
Broadfin Capital
New York
$4.1M +$4.23M +528,571 New
BlackRock
5
BlackRock
New York
$3.68M +$3.8M +475,079 New
SCM
6
Sio Capital Management
New York
$2.69M +$2.77M +346,410 New
Millennium Management
7
Millennium Management
New York
$2.57M +$2.65M +331,332 New
SI
8
Sofinnova Investments
California
$1.96M +$2.03M +253,089 New
ECM
9
Endurant Capital Management
California
$1.8M +$1.86M +232,048 New
JAM
10
JW Asset Management
Florida
$1.74M +$1.8M +225,000 New
NC
11
Nexthera Capital
New York
$935K +$965K +120,620 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$881K +$910K +113,684 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$668K +$691K +86,316 New
Northern Trust
14
Northern Trust
Illinois
$615K +$636K +79,462 New
Charles Schwab
15
Charles Schwab
California
$296K +$305K +38,074 New
O
16
OppenheimerFunds
New York
$259K +$268K +33,474 New
Morgan Stanley
17
Morgan Stanley
New York
$185K +$191K +23,811 New
State Street
18
State Street
Massachusetts
$152K +$157K +19,600 New
California State Teachers Retirement System (CalSTRS)
19
California State Teachers Retirement System (CalSTRS)
California
$137K +$141K +17,655 New
Deutsche Bank
20
Deutsche Bank
Germany
$111K +$116K +14,521 New
TA
21
Teachers Advisors
New York
$101K +$105K +13,082 New
OAM
22
Oxford Asset Management
United Kingdom
$94K +$97.5K +12,179 New
TCIM
23
TIAA CREF Investment Management
New York
$92K +$94.9K +11,859 New
LCM
24
Laurion Capital Management
New York
$78K +$80K +10,000 New
AIG
25
American International Group
New York
$50K +$51.4K +6,420 New
1
2

RVLP Hedge Fund Activity: Q4 2018 in Review

34 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2018, worth a combined $50.9M.

Buyers outnumbered sellers: 34 funds opened new RVLP positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $12M.

  • 34 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2018, up from 0 in Q3 2018.
  • Funds reported $50.9M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2018.
  • 34 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2018 and 0 closed out, a net change of +34 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2018 was Great Point Partners, an estimated $12M added.

Based on aggregated 13F filings for Q4 2018.